Morgan Stanley Spring Works Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 895,575 shares of SWTX stock, worth $41.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

895,575

Previous 1,997,276 55.16%

Holding current value

$41.9 Million

Previous $72.2 Million 45.23%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$32.5 - $59.93 $35.8 Million - $66 Million	-1,101,701 Reduced 55.16%	895,575 $39.5 Million
Q4 2024 Feb 14, 2025	BUY	$28.61 - $42.55 $16 Million - $23.8 Million	558,641 Added 38.83%	1,997,276 $72.2 Million
Q3 2024 May 14, 2025	BUY	$32.04 - $42.76 $35.6 Million - $47.6 Million	1,112,516 Added 341.14%	1,438,635 $46.1 Million
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $35.6 Million - $47.6 Million	1,112,516 Added 341.14%	1,438,635 $46.1 Million
Q2 2024 May 14, 2025	SELL	$36.06 - $47.62 $60.3 Million - $79.6 Million	-1,671,157 Reduced 83.67%	326,119 $12.3 Million
Q2 2024 Oct 17, 2024	SELL	$36.06 - $47.62 $9.19 Million - $12.1 Million	-254,943 Reduced 43.88%	326,119 $12.3 Million
Q2 2024 Aug 14, 2024	SELL	$36.06 - $47.62 $9.19 Million - $12.1 Million	-254,943 Reduced 43.88%	326,119 $12.3 Million
Q1 2024 Oct 17, 2024	BUY	$36.5 - $52.5 $9.31 Million - $13.4 Million	254,943 Added 78.17%	581,062 $28.6 Million
Q1 2024 Aug 16, 2024	BUY	$36.5 - $52.5 $379,527 - $545,895	10,398 Added 1.82%	581,062 $28.6 Million
Q1 2024 May 15, 2024	BUY	$36.5 - $52.5 $379,527 - $545,895	10,398 Added 1.82%	581,062 $28.6 Million
Q4 2023 Aug 16, 2024	BUY	$18.94 - $37.24 $4.63 Million - $9.11 Million	244,545 Added 74.99%	570,664 $20.8 Million
Q4 2023 Feb 13, 2024	BUY	$18.94 - $37.24 $808,775 - $1.59 Million	42,702 Added 8.09%	570,664 $20.8 Million
Q3 2023 Nov 15, 2023	BUY	$23.12 - $31.38 $4.33 Million - $5.87 Million	187,088 Added 54.88%	527,962 $12.2 Million
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $300,232 - $424,215	12,969 Added 3.96%	340,874 $8.94 Million
Q1 2023 May 15, 2023	SELL	$24.97 - $34.05 $1.04 Million - $1.42 Million	-41,781 Reduced 11.3%	327,905 $8.44 Million
Q4 2022 Feb 14, 2023	SELL	$21.73 - $28.72 $8.39 Million - $11.1 Million	-385,931 Reduced 51.07%	369,686 $9.62 Million
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $6.22 Million - $10.2 Million	257,965 Added 51.84%	755,617 $21.6 Million
Q2 2022 Oct 27, 2022	BUY	$18.36 - $60.07 $6.38 Million - $20.9 Million	347,754 Added 231.99%	497,652 $12.3 Million
Q2 2022 Aug 15, 2022	BUY	$18.36 - $60.07 $6.38 Million - $20.9 Million	347,754 Added 231.99%	497,652 $12.3 Million
Q1 2022 Oct 27, 2022	SELL	$48.97 - $65.46 $17 Million - $22.8 Million	-347,754 Reduced 69.88%	149,898 $8.46 Million
Q1 2022 May 13, 2022	BUY	$48.97 - $65.46 $3.02 Million - $4.03 Million	61,623 Added 69.81%	149,898 $8.46 Million
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $1.33 Million - $1.89 Million	-24,961 Reduced 22.04%	88,275 $5.47 Million
Q3 2021 Nov 15, 2021	BUY	$62.66 - $88.26 $7.1 Million - $9.99 Million	113,236 New	113,236 $7.18 Million

Others Institutions Holding SWTX

# of Institutions

361

Shares Held

63.1M

Call Options Held

5.81M

Put Options Held

2.55M

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.92B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account